BCG vaccination in South African HIV-exposed infants : risks and benefits
dc.contributor.author | Hesseling, A. C. | |
dc.contributor.author | Caldwell, J. | |
dc.contributor.author | Cotton, M. F. | |
dc.contributor.author | Eley, B. S. | |
dc.contributor.author | Jaspan, H. B. | |
dc.contributor.author | Jennings, K. | |
dc.contributor.author | Marais, B. J. | |
dc.contributor.author | Nuttall, J. | |
dc.contributor.author | Rabie, H. | |
dc.contributor.author | Roux, P. | |
dc.contributor.author | Schaaf, H. Simon | en_ZA |
dc.date.accessioned | 2010-12-21T05:51:11Z | |
dc.date.available | 2010-12-21T05:51:11Z | |
dc.date.issued | 2009-02 | |
dc.description | The original publication is available at http://www.samj.org.za | |
dc.format.extent | 4 p. | |
dc.identifier.citation | Hesseling, AC et.al 2009, BCG vaccination in South African HIV-exposed infants - Risks and benefits, South African Medical Journal, vol. 99(2) 88-93, http://www.samj.org.za/index.php/samj | en_ZA |
dc.identifier.issn | 02569574 (printed version) | |
dc.identifier.issn | 20785135 (EISSN) | |
dc.identifier.uri | http://hdl.handle.net/10019.1/5496 | |
dc.language.iso | en_ZA | en_ZA |
dc.publisher | Health and Medical Publishing Group (HMPG) | en_ZA |
dc.rights.holder | Health and Medical Publishing Group (HMPG) | |
dc.subject | BCG vaccine | en_ZA |
dc.subject | DNA polymerase | en_ZA |
dc.subject | Virus DNA | en_ZA |
dc.subject | BCG vaccination | en_ZA |
dc.subject | Drug contraindication | en_ZA |
dc.subject | Health care policy | en_ZA |
dc.subject | Human immunodeficiency virus | en_ZA |
dc.subject | Human immunodeficiency virus infected patient | en_ZA |
dc.subject | Human immunodeficiency virus infection | en_ZA |
dc.subject | Lung tuberculosis | en_ZA |
dc.subject | Lymphadenitis | en_ZA |
dc.subject | Mycobacterium tuberculosis | en_ZA |
dc.subject | Risk benefit analysis | en_ZA |
dc.subject | Single drug dose | en_ZA |
dc.subject | South Africa | en_ZA |
dc.subject | Vertical transmission | en_ZA |
dc.subject | World health organization | en_ZA |
dc.subject | Disease transmission | en_ZA |
dc.subject | Drug administration | en_ZA |
dc.subject | Immunology | en_ZA |
dc.subject | Infants | en_ZA |
dc.subject | Newborns | en_ZA |
dc.subject | Risk assessment | en_ZA |
dc.subject | Serodiagnosis | en_ZA |
dc.subject | Tuberculosis | en_ZA |
dc.subject | Adjuvants | en_ZA |
dc.subject | Immunologic | en_ZA |
dc.subject | Drug administration schedule | en_ZA |
dc.subject | Health policy | en_ZA |
dc.subject | HIV infections | en_ZA |
dc.subject | HIV Seronegativity | en_ZA |
dc.subject | Risk assessment | en_ZA |
dc.title | BCG vaccination in South African HIV-exposed infants : risks and benefits | en_ZA |
dc.type | Article | en_ZA |